🔎 Trials Near Me

Home › NCT07856706

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

RecruitingPhase 1Healthy volunteers welcome

A Phase 1, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-7828, and to Evaluate the Effect of Food on ABBV-7828 Pharmacokinetics in Healthy Adult Subjects

Who can join

Ages 18 to 65 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Individuals between 18 to 65 years of age at the time of screening.
* BMI is \<= 18.0 to \>= 32.0 kg/m2.
* A condition of general good health, based upon the results of a medical history, physical evaluations, vital signs, laboratory profile and a 12-lead ECG.

Exclusion Criteria:

* History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
* Has any clinically significant ECG abnormalities including the following:

  * Evidence of 2nd or 3rd degree atrial ventricular (AV) block at screening visit or upon initial confinement
  * QT interval corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) \> 450 msec (males) or \> 460 msec (females) at screening visit or upon initial confinement.
* History of any clinically significant sensitivity or allergy to any medication or food.
* History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption.

About the study

This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.

What is being tested

Sponsor: AbbVie · Participants: 60 · Started: Oct 2, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07856706

Locations in the U.S.

IllinoisAcpru /Id# 283545, Grayslake

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.